Literature DB >> 17492620

IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.

Peter Dubsky1, Hiroaki Saito, Marylene Leogier, Carole Dantin, John E Connolly, Jacques Banchereau, A Karolina Palucka.   

Abstract

Monocytes differentiate into dendritic cells (DC) in response to GM-CSF combined with other cytokines including IL-4 and IL-15. Here, we show that IL15-DC are efficient in priming naive CD8+ T cells to differentiate into melanoma antigen-specific cytotoxic T lymphocytes (CTL). While both melanoma peptide-pulsed IL15-DC and IL4-DC expand high-precursor frequency MART-1-specific CD8+ T cells after two stimulations in vitro, IL15-DC require much lower peptide concentration for priming. IL15-DC are more efficient in expanding gp100-specific CD8+ T cells and can expand CD8+ T cells specific for Tyrosinase and MAGE-3. CTL primed by IL15-DC are superior in their function as demonstrated by (i) higher IFN-gamma secretion, (ii) higher expression of Granzyme B and Perforin, and (iii) higher killing of allogeneic melanoma cell lines, most particularly the HLA-A*0201+ Sk-Mel-24 melanoma cells that are resistant to killing by CD8+ T cells primed with IL4-DC. Supernatants of the sonicated cells demonstrate unique expression of IL-1, IL-8 and IL-15. Therefore, membrane-bound IL-15 might contribute to enhanced priming by IL15-DC. Thus, IL-15 induces myeloid DC that are efficient in priming and maturation of melanoma antigen-specific CTL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492620     DOI: 10.1002/eji.200636329

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  66 in total

1.  The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming.

Authors:  Jacques Banchereau; LuAnn Thompson-Snipes; Sandra Zurawski; Jean-Philippe Blanck; Yanying Cao; Sandra Clayton; Jean-Pierre Gorvel; Gerard Zurawski; Eynav Klechevsky
Journal:  Blood       Date:  2012-04-25       Impact factor: 22.113

Review 2.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  A needle in the 'cancer vaccine' haystack.

Authors:  Anne Gallois; Nina Bhardwaj
Journal:  Nat Med       Date:  2010-08       Impact factor: 53.440

4.  Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.

Authors:  Colin de Haar; Maud Plantinga; Nina Jg Blokland; Niek P van Til; Thijs Wh Flinsenberg; Viggo F Van Tendeloo; Evelien L Smits; Louis Boon; Lotte Spel; Marianne Boes; Jaap Jan Boelens; Stefan Nierkens
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

Review 5.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 6.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.

Authors:  Neale T Hanke; Collin J LaCasse; Claire B Larmonier; Darya Alizadeh; Malika Trad; Nona Janikashvili; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Eur J Immunol       Date:  2014-05-23       Impact factor: 5.532

8.  Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Barry W Ritz; Stephen B Pruett; Elizabeth M Gardner; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

Review 9.  Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.

Authors:  Pawel Kalinski
Journal:  Curr Opin Investig Drugs       Date:  2009-06

10.  Antiviral-activated dendritic cells: a paracrine-induced response state.

Authors:  Antonio V Bordería; Boris M Hartmann; Ana Fernandez-Sesma; Thomas M Moran; Stuart C Sealfon
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.